Gene Therapy Market: By Vector Type, By Disease Type, and Region Forecast 2019-2030

Gene Therapy Market Size, Share, Growth, Trends, and Global Industry Analysis: By Vector Type (Adeno-associated Virus Vector, Lentiviral Vector, Herpes Virus Vector, Others), By Disease Type (Oncological, Disorders, Neurological Disorders, Rare Diseases, Others), and Region Forecast 2019-2030

Gene Therapy Market size was valued at US$ 8.9 billion in 2023 and is poised to grow at a CAGR of 21.6% from 2024-2030. A gene is a functioning hereditary unit of life that contains instructions for performing a certain function. Gene therapy is the advanced treatment for cancer, chronic disease, infectious disease, and blood diseases. On the basis of vector type, the Adeno-associated Virus Vector segment is anticipated to hold the major market value in the forecasting market because the Adeno-associated virus (AAV) is a non-enveloped virus that may be modified to transfer DNA to target cells. It has attracted a lot of interest recently, especially in clinical-stage experimental therapy techniques.

One of the safest gene therapy technologies so far has been the capacity to manufacture recombinant AAV particles devoid of viral genes and DNA sequences of interest for diverse therapeutic purposes. Adeno-associated Virus vectors are used more frequently than other traditional methodologies due to their ease of use. Considering these benefits, the adeno-associated virus segment is anticipated to grow in the forecasting period. Globally, growth in the prevalence of chronic diseases such as cancer, rare genetic disorders, and others is driving the market growth. Moreover, increased government funding, ethical acceptability of gene therapy for cancer treatment, and favorable reimbursement policies contribute to the market growth in the future.

Gene Therapy Market

Key Developments

  • In September 2020, Takeda published the results of a Phase II study of TAK-620 (maribavir) for cytomegalovirus (CMV). The drug is designed to target a specific CMV protein, which may lead to inhibition of CMV DNA replication and encapsulation.
  • In 2020, Etranacogene dezaparvovec is UniQure’s lead gene therapy candidate and includes an AAV serotype 5 (together “AAV-5”) vector incorporating the functional human Factor IX (“FIX”) Padua variant, conducting a pivotal study in patients with severe and moderately severe hemophilia B

Gene Therapy Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

21.6%

Largest Market

North-America

Fastest Growing Market

Asia-Pacific

Gene Therapy Market Dynamics

Increase in the R&D expenditure for the development of novel therapeutics has a substantial impact on the global gene therapy market. Market players are aiming to develop a gene therapy platform with a strategy focused on establishing a transformational portfolio through in-house capabilities and enhancing those capabilities through strategic collaborations, expansion of R&D activities, potential licensing, merger, and acquisition activities. For instance, In March 2021, Elevate Bio, one of the leading biotech companies focused on gene-based therapies, raised USD 525 million to advance its cell and gene therapy technologies.

Gene Therapy Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 8.9 billion

Market CAGR

21.6%

By Vector Type

  • Adeno-associated Virus Vector
  • Lentiviral Vector
  • Herpes Virus Vector
  • Others

By Disease Type

  • Oncological Disorders
  • Neurological Disorders
  • Rare Diseases
  • Other

By Region

  • North America (U.S., Canada)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Key Features of the Report

  • The gene therapy market report provides granular level information about the market size, regional market share, historic market (2019-2023) and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis

Download Free Sample Report

Frequently Asked Questions

The global gene therapy market size was valued at US$ 8.9 billion in 2023 and is projected to grow at a significant CAGR of 21.6% from 2024 to 2030.

Amgen Inc., Bristol-Myers Squibb., Orchard Therapeutics, Gilead Sciences, Novartis AG

Asia-Pacific is the fastest-growing region for Gene Therapy Market

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2. Global Gene Therapy Market Introduction
2.1. Global Gene Therapy Market – Taxonomy
2.2. Global Gene Therapy Market –Definitions
2.2.1. By Vector Type
2.2.2. By Disease Type
2.2.3. By Region
3. Global Gene Therapy Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Current Trends
3.5. Global Gene Therapy Market Dynamic Factors - Impact Analysis
3.6. Mergers, Acquisitions, and Collaborations
4. Global Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Gene Therapy Market, By Vector Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.1. Adeno Virus Vector
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Adeno-associated Virus Vector
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Lentiviral Vector
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Retroviral Vector
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Herpes Virus Vector
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Gene Therapy Market, By Disease Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.1. Oncological Disorders
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Cardiovascular Diseases
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Lentiviral Vector
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Retroviral Vector
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Herpes Virus Vector
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Others
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
7. Global Gene Therapy Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.1. North America
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia Pacific
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. MEA
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Gene Therapy Market - Opportunity Analysis Index, By Vector Type, Disease Type, and Region, 2024 - 2030
8. North America Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.1. Vector Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Adeno Virus Vector
8.1.2. Adeno-associated Virus Vector
8.1.3. Lentiviral Vector
8.1.4. Retroviral Vector
8.1.5. Herpes Virus Vector
8.1.6. Others
8.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Oncological Disorders
8.2.2. Cardiovascular Diseases
8.2.3. Neurological Disorders
8.2.4. Infectious disease
8.2.5. Rare Diseases
8.2.6. Others
8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.3.1. United States
8.3.2. Canada
8.4. North America Gene Therapy Market - Opportunity Analysis Index, By Vector Type, Disease Type, and Country, 2016-2027
8.5. North America Gene Therapy Market Dynamics – Trends
9. Europe Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
9.1. Vector Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Adeno Virus Vector
9.1.2. Adeno-associated Virus Vector
9.1.3. Lentiviral Vector
9.1.4. Retroviral Vector
9.1.5. Herpes Virus Vector
9.1.6. Others
9.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Oncological Disorders
9.2.2. Cardiovascular Diseases
9.2.3. Neurological Disorders
9.2.4. Infectious disease
9.2.5. Rare Diseases
9.2.6. Others
9.3. Country Level Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. UK
9.3.2. Germany
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Europe Gene Therapy Market - Opportunity Analysis Index, By Vector Type, Disease Type, and Country, 2016-2027
9.5. Europe Gene Therapy Market Dynamics – Trends
10. Asia Pacific Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
10.1. Vector Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Adeno Virus Vector
10.1.2. Adeno-associated Virus Vector
10.1.3. Lentiviral Vector
10.1.4. Retroviral Vector
10.1.5. Herpes Virus Vector
10.1.6. Others
10.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Oncological Disorders
10.2.2. Cardiovascular Diseases
10.2.3. Neurological Disorders
10.2.4. Infectious disease
10.2.5. Rare Diseases
10.2.6. Others
10.3. Country Level Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. China
10.3.2. India
10.3.3. ANZ
10.3.4. Japan
10.3.5. Rest of APAC
10.4. Asia Pacific Gene Therapy Market - Opportunity Analysis Index, By Vector Type, Disease Type, and Country, 2016-2027
10.5. Asia Pacific Gene Therapy Market Dynamics – Trends
11. Latin America Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
11.1. Vector Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Adeno Virus Vector
11.1.2. Adeno-associated Virus Vector
11.1.3. Lentiviral Vector
11.1.4. Retroviral Vector
11.1.5. Herpes Virus Vector
11.1.6. Others
11.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Oncological Disorders
11.2.2. Cardiovascular Diseases
11.2.3. Neurological Disorders
11.2.4. Infectious disease
11.2.5. Rare Diseases
11.2.6. Others
11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Rest of LA
11.4. Latin America Gene Therapy Market - Opportunity Analysis Index, By Vector Type, Disease Type, and Country, 2016-2027
11.5. Latin America Gene Therapy Market Dynamics – Trends
12. MEA Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
12.1. Vector Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Adeno Virus Vector
12.1.2. Adeno-associated Virus Vector
12.1.3. Lentiviral Vector
12.1.4. Retroviral Vector
12.1.5. Herpes Virus Vector
12.1.6. Others
12.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Oncological Disorders
12.2.2. Cardiovascular Diseases
12.2.3. Neurological Disorders
12.2.4. Infectious disease
12.2.5. Rare Diseases
12.2.6. Others
12.3. Country Level Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. GCC Countries
12.3.2. South Africa
12.3.3. Rest of MEA
12.4. MEA Gene Therapy Market - Opportunity Analysis Index, By Vector Type, Disease Type, and Country, 2016-2027
12.5. MEA Gene Therapy Market Dynamics – Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Bristol-Myers Squibb Company
13.2.2. Sanofi SA
13.2.3. F. Hoffmann-La Roche Ltd.
13.2.4. Novartis AG
13.2.5. Shire Plc
13.2.6. Gilead Lifesciences, Inc.
13.2.7. REGENXBIO Inc.
13.2.8. Amgen, Inc.
13.2.9. Celgene Corporation
13.2.10. UniQure N.V.
13.2.11. Orchard Therapeutics Plc
14. Research Methodology
15. Key Assumptions and Acronyms

 

Key Market Players

  • Bristol-Myers Squibb Company
  • Sanofi SA
  • Hoffmann-La Roche Ltd.
  • Novartis AG
  • Shire Plc
  • Gilead Lifesciences, Inc.
  • REGENXBIO Inc.
  • Amgen, Inc.
  • Celgene Corporation
  • UniQure N.V.
  • Orchard Therapeutics Plc

Related Industry Reports